{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-059532","form_type":"8-K","ticker":"MGX","cik":"0001785279","company_name":"Metagenomi Therapeutics, Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.098317+00:00","generated_at":"2026-06-02T01:04:20.931365+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Metagenomi Q1 net loss $25.1M, cash $327.4M; regains base editing and RIGS rights from Moderna","bullets":["Q1 net loss $25.1M ($1.19/share) vs $16.1M loss in Q1 2023; collaboration revenue $11.2M.","Cash, equivalents and marketable securities $327.4M including $80.7M net IPO proceeds; runway into 2027.","Regained full global rights to wholly-owned base editors and RIGS; terminated PH1 collaboration with Moderna.","Hemophilia A program: development candidate nomination expected mid-2024; 12-month NHP durability data in 2H 2024.","R&D expenses $31.4M (+56% YoY); base editors expanded genome targetability 5-fold vs SpCas9."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-059532","json":"https://secwatch.observer/filing/0000950170-24-059532.json","markdown":"https://secwatch.observer/filing/0000950170-24-059532.md","text":"https://secwatch.observer/filing/0000950170-24-059532.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785279/000095017024059532/0000950170-24-059532-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785279/000095017024059532/mgx-20240514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T01:04:20.931365+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"60ac4a4d733e9e541ddbb56fd65dd164a03c0c9d","claim":"Metagenomi Therapeutics, Inc. reported quarter ended March 31, 2024 results: revenue $11,159 thousand, net income Net loss of $(25,148) thousand, EPS $(1.19) per share.","evidence_excerpt":"announced its financial results for the quarter ended March 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1785279/000095017024059532/0000950170-24-059532-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2024"},{"label":"Revenue","value":"$11,159 thousand"},{"label":"Net income","value":"Net loss of $(25,148) thousand"},{"label":"EPS","value":"$(1.19) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}